(Saint Louis University, Department of Ophthalmology, St. Louis, Missouri, United States of America)
(Saint Louis University, Department of Ophthalmology, St. Louis, Missouri, United States of America)
Yıl: 2020Cilt: 29Sayı: 4ISSN: 1300-1256 / 2717-7149Sayfa Aralığı: 287 - 291İngilizce

56 0
Brolucizumab: What’s new and newer about it?
Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug approved for use. The aim of this review is to review the HAWK/HARRIER clinical trials, examine post-marketing experience with the drug, and evaluate the packaging/procedural differences with brolucizumab. Brolucizumab is a more potent and longer lasting anti-VEGF agent, and is an important agent that may be used in the treatment of neovascular age-related macular degeneration. Retinal vasculitis is a rare but very serious complication of brolucizumab that the patient and physician must be aware of.
DergiEditoryalErişime Kapalı
  • 1. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:72-84.
  • 2. Avaylon J, Lee S, Gallemore RP. Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration. Int Med Case Rep J. 2020;13:145-52.
  • 3. Witkin AJ, Hahn P, Murray TG, et al. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. J Vitreoretin Dis. 2020;4:269-79.
  • 4. https://www.brolucizumab.info/post-marketing-data. Accessed September 30th, 2020.
  • 5. https://www.brolucizumab.info/sites/brolucizumab_info/fi les/2020-07/ASRS_SRC_report.pdf. Accessed August 31st, 2020.
  • 6. https://www.novartis.com/news/novartis-provides-update-use-and-safety-beovu-patients-wet-amd. Accessed September 30th, 2020.
  • 7. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-98.
  • 8. Gianniou C, Dirani A, Jang L, Mantel I. Refractory Intraretinal or Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Intravitreal Ranizubimab: Functional and Structural Outcome. Retina. 2015;35:1195-201.
  • 9. Guymer RH, Markey CM, McAllister IL, et al. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. Ophthalmology. 2019;126:723-34.
  • 10. Hsu J, Patel SN, Wolfe JD, et al. Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2020.
  • 11. Byeon SH, Kwon OW, Song JH, Kim SE, Park YS. Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):35-42.
  • 12. Casini G, Dal Monte M, Fornaciari I, Filippi L, Bagnoli P. The beta-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res. 2014;42:103-29.
  • 13. Bontzos G, Bagheri S, Ioanidi L, et al. Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. Ophthalmol Retina. 2019.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.